tiprankstipranks
Advertisement
Advertisement

Starcoin Group Details Bond Restructuring as Equity Placement Lapses Amid Going-Concern Efforts

Story Highlights
  • Starcoin Group moves to restructure over HK$1 billion in convertible bonds, extending maturity and cutting interest rates.
  • Lapsed share subscription leaves Starcoin seeking new funding while tightening costs to bolster cash flow and viability.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Starcoin Group Details Bond Restructuring as Equity Placement Lapses Amid Going-Concern Efforts

Claim 30% Off TipRanks

Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an update.

Starcoin Group Limited has issued a quarterly update on its efforts to address an auditor’s disclaimer of opinion over its going concern status, outlining progress and setbacks in debt restructuring, capital raising and cost management. The company has agreed a conditional fourth deed of amendment with major bondholder Extrawell Pharmaceutical Holdings to restructure HK$715 million of convertible bonds plus accrued interest into a larger HK$1.0 billion principal, extend the maturity to 28 July 2030, sharply reduce the interest rate to 0.1% and lower the conversion price to HK$1.0 per share, subject to regulatory and shareholder approvals. A planned equity subscription of 90 million new shares to raise roughly HK$27.78 million lapsed in November 2025 after conditions precedent were not met, leaving the group still searching for new funding via potential equity and debt options. Management is also pursuing stringent cost-control and efficiency measures to improve profitability and operating cash flow, steps that are critical to alleviating liquidity pressures and restoring investor confidence in the company’s long-term viability.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company (stock code 399) that has historically operated in the pharmaceutical and biotech sector and is now repositioning under the Starcoin name. The group’s activities and financial stability have been under scrutiny after its auditor issued a disclaimer of opinion on its ability to continue as a going concern for the year ended 31 March 2025, prompting the company to roll out action plans to strengthen its capital structure and liquidity.

Average Trading Volume: 22,402,047

Technical Sentiment Signal: Sell

Current Market Cap: HK$186.4M

Learn more about 0399 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1